MedTrace Logo

Pharmacokinetics of Oral Morphine and Pharmacogenomics of CYP2D6 and UGT2B7, in an Urban Pediatric Population Presenting for Elective Surgery

NCT01071499 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2017-07-05

No results posted yet for this study

Summary

The purpose of this study is to identify and collect samples from children who have taken a single oral dose of the pain medication morphine, and to determine the genetic differences in the way children metabolize (break down in the body and how it affects them) morphine.

Conditions

Interventions

DRUG

Morphine

One dose of morphine (0.1 mg/kg)

DRUG

Morphine

One dose of morphine (0.2 mg/kg)

DRUG

Morphine

One dose of morphine (0.3 mg/kg)

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Carolyne Montgomery, Dr. · University of British Columbia

  • Gillian Lauder, Dr. · University of British Columbia

  • Katherine Brand, Dr. · University of British Columbia

  • Bruce Carleton, Dr. · University of British Columbia

  • Gideon Koren, Dr. · University of British Columbia

  • Michael Rider, Dr. · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01071499 on ClinicalTrials.gov